Prediction and identification of synergistic compound combinations against pancreatic cancer cells
Open accessAbstract
Resistance to current therapies is common for pancreatic cancer and hence novel treatment options are urgently needed. In this work, we developed and validated a computational method to select synergistic compound combinations based on transcriptomic profiles from both the disease and compound side, combined with a pathway scoring system, which was then validated prospectively by testing 30 compounds (and their combinations) on PANC-1 cells. Some compounds selected as single agents showed lower GI50 values than the standard of care, gemcitabine. Compounds suggested as combination agents with standard therapy gemcitabine based on the best performing scoring system showed on average 2.82-5.18 times higher synergies compared to compounds that were predicted to be active as single agents. Examples of highly synergistic in vitro validated compound pairs include gemcitabine combined with Entinostat, thioridazine, loperamide, scriptaid and Saracatinib. Hence, the computational approach presented here was able to identify synergistic compound combinations against pancreatic cancer cells.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Combination therapies have proven to be an effective strategy for the management of PDAC.
“Combination therapies have proven to be an effective strategy for the management of PDAC.”
From Pyrvinium Pamoate Alone and With Gemcitabine Exhibits Anti‐Pancreatic Cancer Activity in <scp>2D</scp> and <scp>3D</scp> Cell Culture Models (2024) · cites this paper as [29]
The Introduction (page not provided) says gemcitabine is used with nab-paclitaxel as a first-line treatment and that drug combinations have been studied to improve PDAC therapy. But it describes increased efficacy as a potential benefit, while this paper's demonstrated synergies are in pancreatic cancer cells; it does not establish that combination therapies have proven effective for clinical management of PDAC. (LLM, conf=0.86)
Experimental — accuracy not yet measuredBy combining low doses of drugs with distinct mechanisms of action, drug resistance may be overcome, leading to increased efficacy with minimal or no side effects.
“By combining low doses of drugs with distinct mechanisms of action, drug resistance may be overcome, leading to increased efficacy with minimal or no side effects [29]”
From Pyrvinium Pamoate Alone and With Gemcitabine Exhibits Anti‐Pancreatic Cancer Activity in <scp>2D</scp> and <scp>3D</scp> Cell Culture Models (2024) · cites this paper as [29]
The Results (Drug combination screening; page unavailable) report increased killing of pancreatic cancer cells with some low-dose drug combinations, and the Discussion reports synergy for gemcitabine combinations. The paper does not show that these combinations overcome drug resistance or produce minimal or no side effects; its efficacy tests were in cells, not patients. (LLM, conf=0.85)
Experimental — accuracy not yet measuredCombining two drugs with different mechanisms of action and at lower doses may overcome drug resistance and lead to fewer side effects.
“because combining two drugs with different mechanisms of action and at lower doses may overcome drug resistance and lead to fewer side effects [29].”
From Pyrvinium Pamoate Alone and With Gemcitabine Exhibits Anti‐Pancreatic Cancer Activity in <scp>2D</scp> and <scp>3D</scp> Cell Culture Models (2024) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202 · see citing works
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895 · see citing works
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257 · see citing works
ChEMBL: a large-scale bioactivity database for drug discovery
Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr777 · Cited by 4,382 · see citing works
Clonogenic assay of cells in vitro
Franken, N. A. P., Rodermond, H. M., Stap, J., HAVEMAN, J., & Chris van, B. R. E. E. (2006) · Nature Protocols · doi:10.1038/nprot.2006.339 · Cited by 4,202 · see citing works
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848 · see citing works
Sulforhodamine B colorimetric assay for cytotoxicity screening
Vichai, V., & Kirtikara, K. (2006) · Nature Protocols · doi:10.1038/nprot.2006.179 · Cited by 3,679 · see citing works
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.049 · Cited by 3,515 · see citing works
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170 · see citing works
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609 · see citing works
THE TOXICITY OF POISONS APPLIED JOINTLY1
BLISS, C. I. (1939) · Annals of Applied Biology · doi:10.1111/j.1744-7348.1939.tb06990.x · Cited by 2,419 · see citing works
Reich, M. M., Liefeld, T., Gould, J., Lerner, J., Tamayo, P., & Mesirov, J. P. (2006) · Nature Genetics · doi:10.1038/ng0506-500 · Cited by 2,035 · see citing works
Li, D., Xie, K., Wolff, R. A., & Abbruzzese, J. L. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15841-8 · Cited by 1,715 · see citing works
Shemer, A., Grozovski, J., Tay, T. L., Tao, J., Volaski, A., Süß, P., Ardura-Fabregat, A., Gross-Vered, M., Kim, J.-S., David, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07548-5 · Cited by 1,052 · see citing works
The Connectivity Map: A new tool for biomedical research
Lamb, J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2044 · Cited by 945 · see citing works
Geer, L. Y., Marchler-Bauer, A., Geer, R. C., Han, L., He, J., He, S., Liu, C., Shi, W., & Bryant, S. H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp858 · Cited by 875 · see citing works
Sirota, M., Dudley, J. T., Kim, J., Chiang, A. P.-F., Morgan, A. A., Sweet-Cordero, A., Sage, J., & Butte, A. J. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001318 · Cited by 801 · see citing works
Advanced pancreatic carcinoma: current treatment and future challenges
Stathis, A., & Moore, M. J. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.236 · Cited by 791 · see citing works
Combenefit: an interactive platform for the analysis and visualization of drug combinations
Veroli, G. Y. D., Fornari, C., Wang, D. Y. Q., Mollard, S., Bramhall, J. L., Richards, F. M., & Jodrell, D. I. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw230 · Cited by 736 · see citing works
Self-citationZheng, S., Wang, W., Aldahdooh, J., Malyutina, A., Shadbahr, T., Tanoli, Z., Pessia, A., & Tang, J. (2022) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2022.01.004 · Cited by 733 · see citing works
DeepSynergy: predicting anti-cancer drug synergy with Deep Learning
Preuer, K., Lewis, R. P. I., Hochreiter, S., Bender, A., Bulusu, K. C., & Klambauer, G. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx806 · Cited by 651 · see citing works
Self-citationWang, Z. P., Li, Y., Kong, D., Banerjee, S., Ahmad, A., Azmi, A. S., Ali, S. S., Abbruzzese, J. L., Gallick, G. E., & Sarkar, F. H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4312 · Cited by 620 · see citing works
Wei, G., Twomey, D., Lamb, J., Schlis, K. D., Agarwal, J., Stam, R. W., Opferman, J. T., Sallan, S. E., den Boer, M. L., Pieters, R., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.09.006 · Cited by 505 · see citing works
An unbiased oncology compound screen to identify novel combination strategies
O'Neil, J., Benita, Y., Feldman, I., Chenard, M., Roberts, B., Liu, Y., Li, J., Kral, A., Lejnine, S., Loboda, A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0843 · Cited by 407 · see citing works
Holbeck, S. L., Camalier, R., Crowell, J. A., Govindharajulu, J. P., Hollingshead, M., Anderson, L. W., Polley, E., Rubinstein, L., Srivastava, A., Wilsker, D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0489 · Cited by 359 · see citing works
Jahchan, N. S., Dudley, J. T., Mazur, P. K., Flores, N. M., Yang, D., Palmerton, A., Zmoos, A., Vaka, D., Tran, K. Q. T., Zhou, M. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0183 · Cited by 358 · see citing works
Combined Targeted Treatment to Eliminate Tumorigenic Cancer Stem Cells in Human Pancreatic Cancer
Mueller, M., Hermann, P. C., Witthauer, J., Rubio‐Viqueira, B., Leicht, S. F., Huber, S. L., Ellwart, J. W., Mustafa, M., Bartenstein, P., D’Haese, J. G., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.05.053 · Cited by 348 · see citing works
A community computational challenge to predict the activity of pairs of compounds
Community, N.-D., Bansal, M., Yang, J., Karan, C., Menden, M. P., Costello, J. C., Tang, H., Xiao, G., Li, Y., Allen, J., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.3052 · Cited by 321 · see citing works
Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma
Landreville, S., Agapova, O. A., Matatall, K. A., Kneass, Z. T., Onken, M. D., Lee, R. S., Bowcock, A. M., & Harbour, J. W. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0946 · Cited by 290 · see citing works
DrugComb: an integrative cancer drug combination data portal
Zagidullin, B., Aldahdooh, J., Zheng, S., Wang, W., Wang, Y., Saad, J. J., Malyutina, A., Jafari, M., Tanoli, Z., Pessia, A., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz337 · Cited by 263 · see citing works
Transcriptional data: a new gateway to drug repositioning?
Iorio, F., Rittman, T., Ge, H., Menden, M. P., & Sáez-Rodríguez, J. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.07.014 · Cited by 237 · see citing works
Sultana, A., Smith, C. T., Cunningham, D., Starling, N., Tait, D., Neoptolemos, J. P., & Ghaneh, P. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603719 · Cited by 235 · see citing works
Bulusu, K. C., Guha, R., Mason, D. J., Lewis, R. P., Muratov, E. N., KalantarMotamedi, Y., Cokol, M., & Bender, A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.09.003 · Cited by 202 · see citing works
Self-citationPharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer
Espey, M. G., Chen, P., Chalmers, B. P., Drisko, J., Sun, A. Y., Levine, M., & Chen, Q. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.03.007 · Cited by 190 · see citing works
Evolution and dynamics of pancreatic cancer progression
Yachida, S., & Iacobuzio–Donahue, C. A. (2013) · Oncogene · doi:10.1038/onc.2013.29 · Cited by 185 · see citing works
DrugComboRanker: drug combination discovery based on target network analysis
Huang, L. F., Li, F., Sheng, J., Xia, X., Ma, J., Zhan, M., & Wong, S. T. C. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu278 · Cited by 176 · see citing works
Synergistic Drug Combination Prediction by Integrating Multiomics Data in Deep Learning Models
Zhang, T., Zhang, L., Payne, P., & Li, F. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0849-4_12 · Cited by 171 · see citing works
Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine
Donadelli, M., Costanzo, C., Beghelli, S., Scupoli, M. T., Dandrea, M., Bonora, A., Piacentini, P., Budillon, A., Caraglia, M., Scarpa, A., et al. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.05.002 · Cited by 157 · see citing works
Koutsoukas, A., Lowe, R., KalantarMotamedi, Y., Mussa, H. Y., Klaffke, W., Mitchell, J. B. O., Glen, R. C., & Bender, A. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci300435j · Cited by 146 · see citing works
Self-citationShi, Z., Azuma, A., Sampath, D., Li, Y., Huang, P., & Plunkett, W. K. (2001) · PubMed · Cited by 139 · see citing works
DrugComb update: a more comprehensive drug sensitivity data repository and analysis portal
Zheng, S., Aldahdooh, J., Shadbahr, T., Wang, Y., Aldahdooh, D., Bao, J., Wang, W., & Tang, J. P. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab438 · Cited by 128 · see citing works
Fryer, R. A., Barlett, B., Galustian, C., & Dalgleish, A. G. (2011) · PubMed · Cited by 111 · see citing works
Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls
Vlot, A. H. C., Aniceto, N., Menden, M. P., Ulrich-Merzenich, G. S., & Bender, A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.09.002 · Cited by 110 · see citing works
Self-citationA quantitative FastFUCCI assay defines cell cycle dynamics at a single-cell level
Koh, S., Mascalchi, P., Rodríguez, E., Lin, Y., Jodrell, D. I., Richards, F. M., & Lyons, S. K. (2016) · Journal of Cell Science · doi:10.1242/jcs.195164 · Cited by 108 · see citing works
Self-citationGivalos, N., Gakiopoulou, H., Skliri, M., Bousboukea, K., Konstantinidou, A. E., Korkolopoulou, P. A., Lelouda, M., Kouraklis, G. P., Patsouris, E., & Karatzas, G. (2007) · Modern Pathology · doi:10.1038/modpathol.3800719 · Cited by 102 · see citing works
Network Propagation Predicts Drug Synergy in Cancers
Li, H., Li, T., Quang, D. X., & Guan, Y. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0740 · Cited by 100 · see citing works
Drug and disease signature integration identifies synergistic combinations in glioblastoma
Stathias, V., Jermakowicz, A. M., Maloof, M. E., Forlin, M., Walters, W. M., Suter, R. K., Durante, M. A., Williams, S. L., Harbour, J. W., Volmar, C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07659-z · Cited by 99 · see citing works
Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma
Cook, N., Frese, K. K., Bapiro, T. E., Jacobetz, M. A., Gopinathan, A., Miller, J. L., Rao, S. S., Demuth, T., Howat, W., Jodrell, D. I., et al. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20111923 · Cited by 97 · see citing works
MUC1 regulates PDGFA expression during pancreatic cancer progression
Sahraei, M., Roy, L. D., Curry, J., Teresa, T., Nath, S., Besmer, D. M., Kidiyoor, A., Dalia, R., Gendler, S. J., & Mukherjee, P. (2012) · Oncogene · doi:10.1038/onc.2011.651 · Cited by 84 · see citing works
Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer
Chien, W., Sun, Q.-Y., Lee, K. L., Ding, L.-W., Wuensche, P., Torres-Fernandez, L. A., Tan, S. Z., Tokatly, I., Zaiden, N., Poellinger, L., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.01.002 · Cited by 80 · see citing works
In silico drug combination discovery for personalized cancer therapy
Jeon, M., Kim, S., Park, S., Lee, H., & Kang, J. (2018) · BMC Systems Biology · doi:10.1186/s12918-018-0546-1 · Cited by 79 · see citing works
Charting the Fragmented Landscape of Drug Synergy
Meyer, C. T., Wooten, D. J., Lopez, C. F., & Quaranta, V. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.01.011 · Cited by 79 · see citing works
Humbert, M., Castéran, N., Letard, S., Hanssens, K., Iovanna, J., Finetti, P., Bertucci, F., Bader, T., Mansfield, C. D., Moussy, A., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009430 · Cited by 78 · see citing works
Yamasawa, K., Nio, Y., Dong, M., Yamaguchi, K., & Itakura, M. (2002) · PubMed · Cited by 78 · see citing works
Jung, K. H., Choi, I.-K., Lee, H., YAN, H. H., Son, M. K., Ahn, H. M., Hong, J., Yun, C., & Hong, S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.009 · Cited by 78 · see citing works
Bocci, G., Fioravanti, A., Orlandi, P., Bernardini, N., Collecchi, P., Tacca, M. D., & Danesi, R. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602720 · Cited by 75 · see citing works
CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus
Koh, S., Courtin, A., Boyce, R. J., Boyle, R. G., Richards, F. M., & Jodrell, D. I. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3347 · Cited by 64 · see citing works
Self-citationWagner, A., Cohen, N., Kelder, T., Amit, U., Liebman, E., Steinberg, D. M., Radonjić, M., & Ruppin, E. (2015) · Molecular Systems Biology · doi:10.15252/msb.20145486 · Cited by 60 · see citing works
Chien, W., Lee, D. H., Zheng, Y., Wuensche, P., Alvarez, R., Wen, D. L., Aribi, A. M., Thean, S. M., Doan, N., SAID, J. W., et al. (2013) · Molecular Carcinogenesis · doi:10.1002/mc.22024 · Cited by 59 · see citing works
Regan, K., Xu, J., DiVincenzo, M. J., Duggan, M. C., Shakya, R., Na, R., Carson, W. E., Payne, P., & Li, F. (2019) · npj Systems Biology and Applications · doi:10.1038/s41540-019-0085-4 · Cited by 57 · see citing works
Vogl, U. M., Andalibi, H., Klaus, A., Vormittag, L., Schima, W., Heinrich, B., Kafka, A., Winkler, T., & Öhler, L. (2019) · BMC Cancer · doi:10.1186/s12885-018-5240-6 · Cited by 55 · see citing works
Stratification and prediction of drug synergy based on target functional similarity
Yang, M., Jaaks, P., Dry, J. R., Garnett, M. J., Menden, M. P., & Sáez-Rodríguez, J. (2020) · npj Systems Biology and Applications · doi:10.1038/s41540-020-0136-x · Cited by 55 · see citing works
Targeting cancer stem cells with dietary phytochemical - Repositioned drug combinations
Chan, M. M.-Y., Chen, R., & Fong, D. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.06.034 · Cited by 52 · see citing works
Benjamin, D. I., Louie, S. M., Mulvihill, M. M., Kohnz, R. A., Li, D. S., Chan, L. G., Sorrentino, A., Bandyopadhyay, S., Cozzo, A. J., Ohiri, A., et al. (2014) · ACS Chemical Biology · doi:10.1021/cb5001907 · Cited by 51 · see citing works
Saif, M. W. (2006) · PubMed · Cited by 42 · see citing works
Wong, F. Y., Liem, N. L. M., Xie, C., Yan, F. L., Wong, W. C., Wang, L., & Yong, W. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050786 · Cited by 38 · see citing works
Liu, Y., & Zhao, H. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw509 · Cited by 38 · see citing works
Molecular fingerprinting of bovine mastitis-associated Staphylococcus aureus isolates from India
Annamanedi, M., Sheela, P., Sundareshan, S., Isloor, S., Gupta, P., Jasmeen, P., Gargi, M., Mallick, S., & Hegde, N. R. (2021) · Scientific Reports · doi:10.1038/s41598-021-94760-x · Cited by 37 · see citing works
Systematic Quality Control Analysis of LINCS Data
Cheng, L., & Li, L. (2016) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12107 · Cited by 33 · see citing works
Kim, I. Y., Shim, M. J., Lee, D. M., Lee, A. R., Kim, M. A., Yoon, M. J., Kwon, M. R., Lee, H. I., Seo, M. J., Choi, Y. W., et al. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.12.006 · Cited by 33 · see citing works
Perturbational Gene-Expression Signatures for Combinatorial Drug Discovery
Huang, C.-T., Hsieh, C.-H., Chung, Y.-H., Oyang, Y.-J., Huang, H., & Juan, H. (2019) · iScience · doi:10.1016/j.isci.2019.04.039 · Cited by 31 · see citing works
Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison
Sultana, A., Ghaneh, P., Cunningham, D., Starling, N., Neoptolemos, J. P., & Smith, C. T. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-192 · Cited by 31 · see citing works
Tu, M., Li, H., Lv, N., Xi, C., Lu, Z., Wei, J., Chen, J., Guo, F., Jiang, K., Song, G., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0619-6 · Cited by 30 · see citing works
Jin, X., & Wu, Y. (2014) · The Anatomical Record · doi:10.1002/ar.22897 · Cited by 28 · see citing works
Zhou, Y., Sridhar, R., Shan, L., Sha, W., Gu, X., & Sukumar, S. V. (2012) · Cancer Investigation · doi:10.3109/07357907.2011.640653 · Cited by 27 · see citing works
Guo, J., Li, J., Zhao, Y.-P., Zhou, L., Cui, Q., Zhou, W., Zhang, T., & You, L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120332 · Cited by 27 · see citing works
KalantarMotamedi, Y., Eastman, R. T., Guha, R., & Bender, A. (2018) · Malaria Journal · doi:10.1186/s12936-018-2294-5 · Cited by 23 · see citing works
Self-citationQuantitative modeling of dose–response and drug combination based on pathway network
Gu, J., Zhang, X., Ma, Y., Li, N., Luo, F., Cao, L., Wang, Z., Yuan, G., Chen, L., Xiao, W., et al. (2015) · Journal of Cheminformatics · doi:10.1186/s13321-015-0066-6 · Cited by 22 · see citing works
Gysin, S., Paquette, J., & McMahon, M. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0188 · Cited by 19 · see citing works
Identification of pathways associated with chemosensitivity through network embedding
Wang, S., Huang, E. W., Cairns, J., Peng, J., Wang, L., & Sinha, S. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006864 · Cited by 17 · see citing works
KalantarMotamedi, Y., Ejeian, F., Sabouhi, F., Bahmani, L., Nejati, A. S., Bhagwat, A. M., Ahadi, A. M., Tafreshi, A. P., Nasr‐Esfahani, M. H., & Bender, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-91629-x · Cited by 16 · see citing works
Self-citationA simple gene set-based method accurately predicts the synergy of drug pairs
Hsu, Y.-C., Chiu, Y., Chen, Y., Hsiao, T.-H., & Chuang, E. Y.-Y. (2016) · BMC Systems Biology · doi:10.1186/s12918-016-0310-3 · Cited by 15 · see citing works
Xu, J., Regan, K., Deng, S., Carson, W. E., Payne, P., & Li, F. (2017) · Pacific Symposium on Biocomputing (PSB) · doi:10.1142/9789813235533_0009 · Cited by 12 · see citing works
Ma, Y. T., Leonard, S. M., Gordon, N. S., Anderton, J. A., James, C. D., Huen, D. S., Woodman, C. B. J., & Palmer, D. H. (2017) · Oncotarget · doi:10.18632/oncotarget.18879 · Cited by 5 · see citing works
Chigaev, A., Sklar, L. A., Schrader, R., Stephens, N., Raissy, H., & Winter, S. S. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.448 · Cited by 3 · see citing works
Effect of triptolide on gemcitabine-mediated apoptosis in pancreatic cancer cell lines.
Wang, W., & Lin, W. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.e22043 · Cited by 1 · see citing works
Flagged first, then by citations
2 of the 88 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Using Transcriptomics and Cell Morphology Data in Drug Discovery: The Long Road to Practice
Pruteanu, L.-L., & Bender, A. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00015 · Cited by 23 · see citing works
Self-citationMa, Y., Hong, X., Wu, F., Xu, X., Li, R., Zhong, J., Zhou, Y., Liu, S., Zhan, J., & Xü, W. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01055-0 · Cited by 15 · see citing works
Serala, K., Bai, J., & Prince, S. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70222 · Cited by 6 · see citing works
Maietta, I., Domínguez-Arístegui, P., Álvarez, I. G., Atanes, O. R., Fontán, E. M. G., Teijeira, S., González‐Fernández, Á., & Simón‐Vázquez, R. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126155 · Cited by 5 · see citing works
The histone deacetylase inhibitor Scriptaid targets G-quadruplexes
Sánchez-Martín, V., Ružić, D., Tello-Lopez, M. J., Ortiz-Morales, A., Murciano‐Calles, J., Soriano, M., Nikolic, K. M., & Garcia-Salcedo, J. A. (2025) · Open Biology · doi:10.1098/rsob.240183 · Cited by 2 · see citing works
Behdarvandiyan, P., Jafarpour, F., Hajian, M., Andani, M. R., Moradi-Hajidavaloo, R., Rahimi, M., KalantarMotamedi, Y., Hosseini, M., Nasr‐Esfahani, M. H., & Nasr‐Esfahani, M. H. (2025) · Theriogenology · doi:10.1016/j.theriogenology.2025.117735 · Cited by 1 · see citing works
Self-citationKalantarMotamedi, Y., Khoogar, R., Phelps, D. A., Houghton, P. J., & Bender, A. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3981105
Self-citation
- Authors
- KalantarMotamedi, Y., Choi, R. J., Koh, S.-B., Bramhall, J. L., Fan, T.-P., & Bender, A.
- Affiliations
- University of Cambridge (GB)
- Corresponding author
- Bender, Andreas
- Venue
- iScience
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 24
- Issue
- 9
- Pages
- 103080
- ISSN
- 2589-0042 (ISSN-L)
- PMC
- PMC8456050
- OpenAlex
- W3197369013
- Cited by
- 8
- References
- 88
- Citations by year
- 2025: 3 · 2024: 2 · 2023: 2 · 2021: 1
- FWCI
- 0.66
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- iScience (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Explore Bristol Research (submittedVersion, cc-by)
- Bristol Research (University of Bristol) (submittedVersion, cc-by)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- European Research Council
- ERC
- Topics
- Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Keywords
- pancreatic cancer, synergistic drug combination, drug repurposing, transcriptomic profiles, PANC-1 cells, gemcitabine, entinostat, thioridazine, loperamide, Scriptaid, saracatinib, drug synergy prediction, combination therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
